Clinical Trials | May 25, 2026
AstraZeneca breast cancer drug wins key EU backing after cutting progression risk by 56%
The recommendation is powered by blockbuster results from the pivotal Phase III SERENA-6 trial
The recommendation is powered by blockbuster results from the pivotal Phase III SERENA-6 trial
The decision marks a key step in the centralized EU review process
The company is also highlighting early-stage innovation in antibody-drug conjugates and in vivo CAR-T therapy
The company said the breadth of its showcase reflects “progress from its differentiated oncology pipeline in solid tumors and hematologic malignancies,”
With standout ADC and t-cell engager response data across hard-to-treat cancers
Across more than 85 abstracts, AstraZeneca will showcase 10 approved medicines and 13 potential new therapies
Highlights strong Vibegron results in older men & real-world prostate cancer insights
The trial will assess Precem-TcT, both as monotherapy and in combination with bevacizumab, in patients whose disease has progressed after or become resistant to standard treatments
Transition to a fermentation-based globally integrated CDMO platform
More than 450 public and private health technology solutions have integrated with the Ayushman Bharat Digital Mission ecosystem
Subscribe To Our Newsletter & Stay Updated
